Phase 2 N=137 A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease
Parkinson Disease
Primary: Incidence of Treatment-emergent Adverse Events (TEAEs) — 19; 21; 21; 21 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition
Advanced Head and Neck Squamous Cell Carcinoma · Recurrent Head and Neck Squamous Cell Carcinoma · Metastatic Head-and-neck Squamous-cell Carcinoma
Primary: Overall Response - — 40.0 percentage of participants
Phase 2 N=21 Cabozantinib and Pembrolizumab in Metastatic Pancreas
Pancreatic Cancer
Primary: Progression-free Survival — 2 Participants
Phase 2 N=22 A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)
Cystic Fibrosis · Bronchiectasis
Primary: Occurrence of Any Treatment Emergent Adverse Events — 85.7; 93.3 Percentage of participants
Phase 2 N=142 A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain
Endometriosis
Primary: Change in Dysmenorrhea (DYS) Measured by Numeric Rating Scale (NRS) From Baseline to Week 12 (Percentage Change) — -27.35; -34.72; -41.57; -18.61 percentage of change…
Phase 2 N=47 A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
MPN (Myeloproliferative Neoplasms)
Primary: Percentage of Participants Who Achieved Complete Response (CR) as Determined by Investigator Assessment According to the Response Criteria for Myeloid/Lymphoid Neoplasms…
Phase 2 N=1,364 Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)
Dengue
Primary: Dengue Virus (DENV)-Neutralizing Antibody Titers as Measured by Virus Reduction Neutralization Test (VRNT) — 608.55; 703.19; 773.96; 109.05 Titer — p=<0.001
Phase 2 N=356 A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
Advanced Cancer
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) - Part 1 A and 1 B — 6; 11; 10; 1 Participants
Phase 2 N=59 A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica
Chronic Pruritus in Adult Subjects With Notalgia Paresthetica (NP)
Primary: Percent Change From Baseline in Weekly Mean of the Daily 24-hour Worst Itch-Numeric Rating Scale (WI-NRS) Score at Week 4. — -44.37; -50.37 percentage of change from…
Phase 2 N=506 Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
End-Stage Renal Disease · End-Stage Kidney Disease · Kidney Failure, Chronic
Primary: Time to First Arteriovenous Graft (AVG) Thrombosis Event — 23.80; 22.98; 30.17 events per 100 person-years — p=0.470
Phase 2 N=611 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
Advanced Solid Tumors · Triple Negative Breast Cancer · Ovarian Cancer
Primary: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Investigator Assessment — 22.6; 25.8 Percentage of Participants
Phase 2 N=428 A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
Dyslipidemia
Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 — -31.19; -33.83; -41.09; -46.62 Percent Change (%) — p=< 0.001
Phase 2 N=60 Evaluation of AMG 714 for Vitiligo
Vitiligo
Primary: Proportion of Participants Achieving a ≥ 35% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI35) at Week 24 — 0.150; 0.053 Proportion of…
Phase 2 N=53 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
Biochemical Recurrence of Malignant Neoplasm of Prostate
Primary: Safety and Tolerability — 8; 8; 0; 0 Participants
Phase 2 N=48 SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver
Stage IV Uveal Melanoma
Primary: Clinical Benefit Rate of Previously Treated and Naive Patients — 0; 0; 7; 6 Participants